查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1496027

全球腸道管理系統市場 - 2024 年至 2029 年預測

Global Bowel Management Systems Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 138 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

腸道管理系統市場預計將以 4.13% 的複合年成長率成長，從 2022 年的 811,927,000 美元增至 2029 年的 1,077,824,000 美元。

腸道管理系統是一種醫療應用，旨在幫助腸道控制受損的人，包括患有神經系統疾病的人，如神經源性腸功能障礙、脊髓相關損傷 它和多種類型的硬化症。由小工具、治療和介入組成。這些系統的主要目的是觀察、分析和監測排便情況，避免大便失禁和糞便滯留，並提高這些人的生活品質。這些系統包括飲食調整、藥物治療以及使用直腸栓劑、腸道靜脈切開術和腸道灌注系統等治療物品。

全球腸道管理系統產業包括用於解決腸道功能障礙和推進腸道管理的產品和解決方案的製造、分銷和銷售。促成這一市場擴張的變數主要是由於神經病變的主導地位、老年人口的增加、創新技術的進步、以患者為中心的方法以及醫療保健利用率的提高。

脊髓損傷、不同的硬化症和某些神經系統混亂等神經系統疾病可能導致腸道破損，從而推動對腸道管理安排的需求。科技進步為日常生活中監督腸道功能障礙的人們提供了更高的生存能力、安慰和舒適度。

市場促進因素：

  • 腸道疾病發病率的上升和老年人口的增加預計將推動腸道管理系統市場的發展。

腸道管理系統透過幫助治療大便失禁，幫助患者保持皮膚清潔、一塵不染。該裝置是插入直腸的柔軟導管，用於容納和轉移糞便。技術先進的腸道管理設備的可用性正在迅速增加，老年人口也在增加。

排便障礙相關疾病的增加是推動腸道管理系統市場成長的主要因素。此外，人們對這些設備可用性的認知不斷提高，再加上滿足許多未滿足需求的新設備的推出，都有助於腸道管理系統市場的成長。

根據 2024 年 4 月的 AANP資料，大腸激躁症(IBS) 是一種慢性胃腸道疾病，影響著美國2,500 萬至4,500 萬人，並限制了他們的工作、上學和維持人際關係的能力。儘管影響了全球 5-10% 的人口，但 75% 的 IBS 患者可能未被診斷出來。尋求治療的患者可能要等待長達四年的醫療保健。此外，新興經濟體有利的報銷方案和腸道管理系統的技術進步正在推動市場成長。

大便不一致問題在成年人中更為常見，這加強了腸道管理系統市場。

隨著年齡的成長，我們的認知功能會下降，注意力和控制血液循環的能力也會下降。排便不規律可能是一個新出現的問題，尤其是在人口老化的情況下，這推動了對腸道管理框架的需求。這些因素包括世界人口的老化、神經系統疾病、糖尿病和某些胃腸道疾病等持續存在的疾病，這些疾病可能導致腸道不規則。

此外，手術和治療後可能會導致暫時或慢性腸道功能障礙，因此有效管理這些問題對個人來說極為重要。由於這些因素以及解決老齡化社會中日益增加的不便問題的需要，腸道管理系統市場預計將成長。許多成年人患有大便失禁，這刺激了對腸道管理框架的需求。

由於患有腸道相關疾病和併發症的人數不斷增加，結腸造口袋的使用正在增加。推而廣之，腸躁症等感染疾病在老化族群中較為常見。根據美國疾病管制與預防中心 2022 年 4 月的資料，IBD（包括克隆氏症和潰瘍性大腸炎）影響著 1.3% 的美國成年人口（310 萬成年人）。

預計北美地區將主導市場佔有率。

由於嚴重感染疾病數量的增加、設備齊全的醫療保健系統和發達的醫療保健框架，預計北美地區在預測期內其行業佔有率將固有增加。此外，提高患者對各種腸道問題風險的認知也有望有助於該地區的市場擴張。

由於人口中腸癌和大腸癌等嚴重的數量不斷增加，預計北美國家將在估計期間保持適度的市場規模並為市場擴張做出貢獻。因此，腸道疾病影響老年人口的可能性正在擴大。

主要進展

  • 2024 年 2 月，康樂保推出了 Peristen(R) Light，這是一種經肛門沖洗裝置，可為慢性便秘和大便失禁等腸道疾病患者提供支援。 Peristine Lite 是基於康樂保 20 年大容量灌注設備 Peristine Plus 的經驗而開發的。
  • 2022 年 4 月 - Microbiotica 獲得克隆氏症和結腸炎基金會的資助，用於開發治療潰瘍性大腸炎(UC) 的活細菌療法 (LBT)。 MB310 是一種完全定義的 LBT，包含 10 種細菌菌株，其開發由克隆氏症和結腸炎基金會的 IBD Ventures 計劃資助，用於 cGMP 製造和臨床實驗新藥備案。
  • 2022 年 2 月 - 領先的造造口護理產品製造商康樂保在新加坡推出 SenSura(R) Mio。我們是東南亞第一個引進這種創新產品的國家。

我們的產品

  • Bioness 的用於治療週邊神經痛的醫療設備「StimRouter(R) Neuromodulation System」已獲得 FDA核准和 CE 標誌。該系統在歐洲銷售，醫生可以將一個小型植入插入腳踝附近的脛神經來治療大便失禁。該裝置具有微創性，可輕鬆植入脛神經附近。
  • BARD DIGNISHEILD 糞便管理系統 - 全球領先的醫療設備公司 BD 提供 BARD DIGNISHEILD 糞便管理系統，可保護嬌嫩組織免受洩漏、壓力和摩擦造成的損壞。該系統包括導管組件、60cc 注射器、收集袋和潤滑劑。其他產品包括除臭劑和管夾。
  • Rectobag - B. Braun Melsungen AG 是一家領先的醫療產品製造商，提供大便失禁和腸道管理領域的各種產品，包括 Rectobag 和直腸導管。 Rectobag 是一種封閉式系統，用於重複排便和診斷，長度為 10 厘米，配有錐形連接器、孔轉移管和閉合夾。沖洗導管，也稱為直腸導管，具有顏色編碼的錐形配件、封閉的圓形尖端和兩個橫向定位的孔。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章腸道管理系統的全球市場：依產品

  • 介紹
  • 結腸造口袋
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 灌溉系統
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 神經調節劑
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章腸道管理系統的全球市場：依患者類型

  • 介紹
  • 成人
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 孩子
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章腸道管理系統的全球市場：依最終使用者分類

  • 介紹
  • 醫院
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 門診中心
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 居家護理
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第8章腸道管理系統的全球市場：按地區

  • 介紹
  • 北美洲
    • 依產品
    • 依患者類型
    • 按最終用戶
    • 按國家/地區
  • 南美洲
    • 依產品
    • 依患者類型
    • 按最終用戶
    • 按國家/地區
  • 歐洲
    • 依產品
    • 依患者類型
    • 按最終用戶
    • 按國家/地區
  • 中東/非洲
    • 依產品
    • 依患者類型
    • 按最終用戶
    • 按國家/地區
  • 亞太地區
    • 依產品
    • 依患者類型
    • 按最終用戶
    • 按國家/地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 有競爭力的儀表板

第10章 公司簡介

  • Cogentix Medical
  • Hollister Incorporated
  • Mbh-International A/S
  • Mederi Therapeutics Inc
  • B. Braun Melsungen AG
  • Aquaflush Medical Limited
  • Consure
  • Wellspect health care
  • ConvaTec Group Plc.
  • ProSys International Ltd.
簡介目錄
Product Code: KSI061611766

The global bowel management systems market is projected to grow at a CAGR of 4.13% to reach US$1,077.824 million by 2029, from US$811.927 million in 2022.

The bowel management system consists of medical gadgets, procedures, and interventions meant to assist individuals with impaired bowel control including those with neurological clutter such as neurogenic bowel dysfunction, spinal cord-related injuries, and numerous types of sclerosis. The main goal of these systems is to observe, analyze, and monitor the movement of the bowel, avoid fecal incontinence or stoppage, and upgrade the quality of life for these people. These systems may incorporate dietary adjustments, medicines, and the utilization of therapeutic gadgets such as rectal suppositories, bowel purges, or bowel irrigation systems.

The worldwide bowel management systems industry incorporates the manufacturing, distribution, and sales of items and solutions outlined to address bowel dysfunction and progress bowel management. Variables contributing to this market expansion are majorly due to the predominance of neurological clutters, the growing senior-age populace, innovative technological progressions, a patient-centric approach, and rising healthcare use.

Neurological disorders, like spinal cord injuries, different sclerosis, and certain neurological clutters, can result in bowel brokenness, driving the request for bowel administration arrangements. Technological progressions offer moved forward viability, consolation, and comfort for people overseeing bowel dysfunction in their daily lives.

Market Drivers:

  • The increasing number of bowel diseases and the geriatric population are anticipated to boost the bowel management systems market.

The bowel management system helps patients maintain clean, uncontaminated skin by assisting with the treatment of fecal irregularity. The device is a soft catheter that is inserted into the rectum to contain and divert fecal waste. The surge in availability of technologically advanced devices for fecal management and the rise in the geriatric population.

The increase in fecal inconsistency-related disorders is the major factor that is driving the market for bowel management systems to grow. Furthermore, increased awareness of the availability of these devices, combined with the introduction of new devices that address many unserved needs contributes to the bowel management system market's growth.

According to the AANP data of April 2024, Irritable bowel syndrome (IBS), a chronic gastrointestinal condition affecting 25 to 45 million people in the US, can limit their ability to work, attend school, and maintain relationships. Despite affecting 5 to 10% of the global population, 75% of those with IBS may be undiagnosed. Patients seeking medical treatment may wait up to four years before seeing their healthcare provider. Furthermore, favorable reimbursement scenarios in developed economies, as well as technological advancements in bowel management systems, are driving the market growth.

The problem of fecal inconsistency is more prevalent among adults, which will bolster the bowel management systems market.

As individuals age, cognitive function declines, and alertness and control over bloody functions decrease, which is one reason geriatric individuals require assistance. Fecal irregularity, especially within the aging population, maybe a developing concern, driving the request for bowel administration frameworks. Components contributing to this involve the global maturing populace, persistent conditions such as neurological diseases, diabetes, and certain gastrointestinal illnesses, which can cause bowel irregularity.

Additionally, post-surgical and medical treatments can lead to temporary or chronic bowel dysfunction, making it crucial for individuals to manage these issues effectively. The bowel management systems market is expected to grow due to these factors and the need to address the growing issue of fecal inconsistency in the aging population. A large number of adults have fecal incontinence, which is fueling up the requirement for bowel management frameworks.

There is an increment within the utilization of colostomy bags as the number of people enduring illnesses and complications related to the bowel is expanding. In expansion, infections like irritable bowel disorder are more common among the aging population. According to the Centers for Disease Control and Prevention data of April 2022, IBD, including Crohn's disease and ulcerative colitis, affects 1.3% of the US adult population, including 3.1 million adults.

The North American region is predicted to dominate the market share.

The North American region is evaluated to increase essentially in industry share over the projected period owing to the increasing number of severe infections, well-positioned healthcare systems, and well-developed healthcare framework. Moreover, the increasing awareness among patients with respect to the hazards of different bowel issues is additionally anticipated to contribute to this region's market expansion.

Due to an increment in the number of severe illnesses like intestinal cancer and colorectal cancer among the populace, the North American countries are anticipated to hold moderate market size and contribute to its expansion over the estimated period. As a result, the chance of bowel diseases influencing the geriatric population is expanding.

Key Developments:

  • February 2024- Coloplast launched Peristeen(R) Light, a transanal irrigation device designed to help people with bowel disorders, including chronic constipation and fecal incontinence. Peristeen Light is based on 20 years of experience from Coloplast's high-volume gadget, Peristeen Plus. It is instinctive, easy to utilize, and collected in fair two steps with a delicate, adaptable catheter.
  • April 2022- Microbiotica received funding from the Crohn's & Colitis Foundation to develop a Live Bacterial Therapeutic (LBT) for ulcerative colitis (UC). The development of MB310, a fully defined LBT containing 10 bacterial species, is being funded by the Crohn's & Colitis Foundation's IBD Ventures program in preparation for cGMP manufacture and an investigational new drug application. Immune homeostasis can be restored and important UC disease pathology addressed by MB310.
  • February 2022- Coloplast, a leading manufacturer of stoma care products, launched SenSura(R) Mio in Singapore, the first Southeast Asian country to introduce this innovative product.

Company Product:

  • StimRouter(R) Neuromodulation System- Bioness, Inc. has received FDA approval and CE mark for its "StimRouter(R) Neuromodulation System," a medical device for treating peripheral nerve pain. The system, available in Europe, allows physicians to treat fecal or bowel incontinence by inserting a small implant into the tibial nerve near the ankle. The device is minimally invasive and easier to implant near the nerve Tibialis.
  • BARD DIGNISHEILD Stool Management System - BD, a leading global medical equipment company, offers the "BARD DIGNISHEILD Stool Management System" to protect delicate tissues from damage caused by leakage, pressure, or friction. The system incorporates a catheter tube assembly, a 60cc syringe, a collection bag, and a lubricating jelly. Additional products include an odor eliminator and a tube clamp. The system helps patients avoid exposure, tissue damage, and odor.
  • Rectobag - B. Braun Melsungen AG, a leading medical product manufacturer, offers a range of products under its Fecal Incontinence & Bowel Management segment, including a Rectobag and a Rectal Catheter. The Rectobag is a closed system used for repeated intestinal salvage and diagnostics, featuring a conical connector, bore transfer tube, and a 10 cm length with a closing clamp. The Irrigation Catheter, also known as a rectal catheter, has a color-coded cone fitting, a closed rounded tip, and two laterally positioned eyes.

Market Segmentation:

Global Bowel Management Systems Market is segmented and analyzed as below:

By Product

  • Colostomy Bags
  • Irrigation Systems
  • Nerve Modulation Devices
  • Others

By Patient Type

  • Adults
  • Paediatric

By End-User

  • Hospitals
  • Ambulatory Centers
  • Home Care

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL BOWEL MANAGEMENT SYSTEMS MARKET BY PRODUCT

  • 5.1. Introduction
  • 5.2. Colostomy Bags
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Irrigation Systems
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Nerve Modulation Devices
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Others
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLOBAL BOWEL MANAGEMENT SYSTEMS MARKET BY PATIENT TYPE

  • 6.1. Introduction
  • 6.2. Adults
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Paediatric
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness

7. GLOBAL BOWEL MANAGEMENT SYSTEMS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Ambulatory Centers
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Home Care
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness

8. GLOBAL BOWEL MANAGEMENT SYSTEMS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Product
    • 8.2.2. By Patient Type
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Product
    • 8.3.2. By Patient Type
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Product
    • 8.4.2. By Patient Type
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. UK
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Spain
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Others
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Product
    • 8.5.2. By Patient Type
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. Israel
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Product
    • 8.6.2. By Patient Type
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. Japan
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. South Korea
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. India
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Thailand
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Taiwan
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Cogentix Medical
  • 10.2. Hollister Incorporated
  • 10.3. Mbh-International A/S
  • 10.4. Mederi Therapeutics Inc
  • 10.5. B. Braun Melsungen AG
  • 10.6. Aquaflush Medical Limited
  • 10.7. Consure
  • 10.8. Wellspect health care
  • 10.9. ConvaTec Group Plc.
  • 10.10. ProSys International Ltd.